Jeremy Springhorn, Nido Biosciences CEO

From 5AM's nest, neu­ro­science start­up Nido Bio­sciences launch­es with $109M and PhI un­der­way

Af­ter al­most five years in stealth, pre­ci­sion neu­ro­science start­up Nido Bio­sciences emerged Mon­day with $109 mil­lion and a Phase I study al­ready in the works.

The biotech, led by for­mer Sy­ros Phar­ma­ceu­ti­cals busi­ness chief and near­ly three-decade Alex­ion vet­er­an Je­re­my Spring­horn, is cre­at­ing new small mol­e­cules for neu­ro­log­i­cal dis­eases and aims to re­turn cells to a healthy state.

The Wa­ter­town, MA-based biotech formed in 5AM Ven­tures’ so-called 4:59 Ini­tia­tive, which has spawned gene ther­a­py mak­er Ho­mol­o­gy Med­i­cines, cell ther­a­py biotech En­so­ma and on­col­o­gy-fo­cused Ideaya Bio­sciences, among oth­ers.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.